Literature DB >> 1512693

Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease.

R D'Amelio1, R Biselli, R Nisini, P M Matricardi, A Aiuti, I Mezzaroma, E Pinter, O Pontesilli, F Aiuti.   

Abstract

Human immunodeficiency virus (HIV) infection is characterized by a progressive decline in immune functions. The behavior of B-cell clones specifically engaged in the anti-HIV response could play a relevant role in the pathogenesis of such impairment. The spectrotype observed on isoelectric focusing and reverse blotting after antigen challenge is the serum image of antigen-specific B-cell activity and may provide some insight into Ag-dependent B-cell clone recruitment. In this study, we examined the spectrotype of anti-gp120 antibodies in a group of sera from 56 HIV-infected patients, belonging to groups II, III, and IV of the Centers for Disease Control classification, as well as in a group of 31 sera from 12 patients in a 21-month follow-up evaluation (range 7-36 months). All tested sera were positive for gp120 antibodies on Western blot. In the first group of 56 HIV-infected subjects, only 19 displayed well-focused banding patterns. Among these, the spectrotype was found to be consistently oligoclonal, thus confirming clonal restriction of anti-gp120 antibodies previously described by other investigators. No correlation could be established between a particular spectrotype and phase of the disease. The follow-up evaluation in the second group of 31 sera revealed the tendency in each patient to maintain the same spectrotype throughout the course of the disease. These findings confirm clonal restriction of anti-gp120 antibodies in HIV infection and suggest that the number of B-cell clones recruited in the anti-gp120 response remains stable over the course of the disease, at least in the time range explored by us.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512693

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  11 in total

1.  Incidence of Helicobacter pylori infection in a cohort of Italian military students.

Authors:  R Biselli; M Fortini; P M Matricardi; T Stroffolini; R D'Amelio
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Authors:  P Seiler; B M Senn; P Klenerman; U Kalinke; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

5.  Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.

Authors:  S Müller; D H Margolin; P L Nara; W G Alvord; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

6.  Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Authors:  Georgia D Tomaras; James M Binley; Elin S Gray; Emma T Crooks; Keiko Osawa; Penny L Moore; Nancy Tumba; Tommy Tong; Xiaoying Shen; Nicole L Yates; Julie Decker; Constantinos Kurt Wibmer; Feng Gao; S Munir Alam; Philippa Easterbrook; Salim Abdool Karim; Gift Kamanga; John A Crump; Myron Cohen; George M Shaw; John R Mascola; Barton F Haynes; David C Montefiori; Lynn Morris
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy.

Authors:  R Biselli; V Del Bono; M Anselmo; A Canessa; G Mazzarello; R D'Amelio; D Bassetti
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

9.  Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer.

Authors:  R Biselli; D Vaira; R Nisini; M Miglioli; L Menegatti; L Barbara; R D'Amelio
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

10.  Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4.

Authors:  P K Tsai; M W Bruner; J I Irwin; C C Ip; C N Oliver; R W Nelson; D B Volkin; C R Middaugh
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.